Iovance Biotherapeutics Inc IOVA.OQ IOVA.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The San Carlos California-based company is expected to report a 11,327.2% increase in revenue to $81.705 million from $715 thousand a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Iovance Biotherapeutics Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.3% in the last three months.
Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $18.00, above its last closing price of $3.50.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.27 | -0.27 | -0.26 | Beat | 2.7 |
Sep. 30 2024 | -0.31 | -0.30 | -0.28 | Beat | 6.4 |
Jun. 30 2024 | -0.35 | -0.35 | -0.34 | Beat | 3.8 |
Mar. 31 2024 | -0.42 | -0.42 | -0.42 | Met | 0.6 |
Dec. 31 2023 | -0.43 | -0.43 | -0.45 | Missed | -4.3 |
Sep. 30 2023 | -0.46 | -0.45 | -0.46 | Missed | -1.3 |
Jun. 30 2023 | -0.82 | -0.80 | -0.47 | Beat | 41 |
Mar. 31 2023 | -0.77 | -0.74 | -0.50 | Beat | 32.9 |
This summary was machine generated May 6 at 21:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。